2025 Communication Vaccines 
European Pharmaceutical Review
DECEMBER 19, 2023
Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.
European Pharmaceutical Review
JANUARY 31, 2023
A new strategy for 2023-2025 by the Medicines Patent Pool (MPP) aims to reduce access inequities, by improving the availability and affordability of health products in low- and middle-income countries (LMICs). Part of the plan includes enabling 30 million people to access MPP-licensed products each year by 2025.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 21, 2022
This Moderna Innovation and Technology Centre (MITC) is expected to offer access to a locally produced future mRNA vaccine portfolio against respiratory viruses, subject to regulatory evaluation and licensure. Additionally, the centre is anticipated to have to capacity to make up to 250 million doses of vaccines per year.
Putting Patients First Blog
SEPTEMBER 9, 2024
CY 2025 PFS proposed rule). The continuation of audio-only communication options remains essential. Preventive Services The expansion of preventive services, including hepatitis B vaccinations and colorectal cancer screenings, is a positive development for public health.
Pharmaceutical Technology
JANUARY 20, 2023
In 2020, Moderna made a net loss of $747 million while its investigational mRNA vaccines were under development. However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. billion in Covid-19 vaccine sales.
Quality Matters
SEPTEMBER 10, 2024
Our team is diligent about maintaining consistent communication with manufacturers and other key stakeholders. Last November, MFDS achieved maturity level 4, which is the highest level in the World Health Organization’s classification of regulatory authorities for pharmaceutical products and vaccines, which was a great honor.
pharmaphorum
MARCH 12, 2021
If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, developed, trialled, approved and manufactured have confirmed just how dynamic the industry can be. And those volumes will only increase.
Expert insights. Personalized for you.
111 
Let's personalize your content